Werner Tschollar is one of the founders of AMYRA and the company’s CEO. He also serves as Chairman of the Board of Directors.
Werner has over 30 years of experience in the pharmaceutical, biotech and financing industries.
He held senior executive R&D positions at Bristol-Myers Squibb Inc., Schering Plough Corp. and Novartis AG. During this time, Werner was instrumentally involved in the development of blockbuster drugs such as Captopril and Paravastatin. He also contributed directly to the scientific and clinical establishment of metabolic syndrome as underlying disease pathology in type II diabetes, obesity, and hypertension.
Later he was founder and CEO of Neurim Pharmaceuticals Ltd., which he led through a successful exit to several pharmaceutical partner companies.
Subsequently he was co-founder and Partner of Ares Life Sciences, a large private equity fund in Geneva.
Werner holds degrees in Medicine (MD), pharmacy (MA) and clinical pharmacology (PhD), and has an MBA.